<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Promising Drug Trials | Memory Support</title>
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
</head>
<body>
    <header>
        <div class="container header-content">
            <div class="logo">
                <i class="fas fa-brain"></i>
                <span>Memory Support</span>
            </div>
            <div class="menu-toggle">
                <i class="fas fa-bars"></i>
            </div>
            <nav>
                <ul>
                    <li><a href="../index.html#stories">Stories</a></li>
                    <li><a href="../index.html#tips">Tips</a></li>
                    <li><a href="../index.html#research">Research</a></li>
                    <li><a href="../index.html#resources">Resources</a></li>
                </ul>
            </nav>
        </div>
    </header>
    
    <main class="main">
        <div class="container">
            <div class="article-content">
                <h1>Promising Drug Trials</h1>
                <p>The Alzheimer's treatment landscape is evolving rapidly, with several promising drugs in late-stage clinical trials:</p>
                <p><strong>Anti-amyloid therapies:</strong> Lecanemab recently received FDA approval, showing 27% slower decline in early Alzheimer's patients. Similar drugs like Donanemab are showing even stronger results in trials, with some patients experiencing near-complete amyloid clearance.</p>
                <p><strong>Tau-targeting drugs:</strong> While most research has focused on amyloid, new drugs targeting tau protein tangles are showing promise. BIIB080 is currently in phase 2 trials using antisense oligonucleotides to reduce tau production.</p>
                <p><strong>Combination therapies:</strong> Researchers are exploring whether combining amyloid-clearing drugs with anti-inflammatory or neuroprotective agents could yield better results. Early trials suggest synergistic effects that may preserve cognitive function longer than single therapies.</p>
                <a href="../index.html#research" class="back-link"><i class="fas fa-arrow-left"></i> Back to Research</a>
            </div>
        </div>
    </main>
    
    <footer>
        <div class="container">
            <div class="footer-content">
                <div class="footer-section">
                    <h3>Memory Support</h3>
                    <p>Providing reliable information and support for families affected by Alzheimer's and dementia.</p>
                    <div class="social-icons">
                        <a href="#"><i class="fab fa-facebook-f"></i></a>
                        <a href="#"><i class="fab fa-twitter"></i></a>
                        <a href="#"><i class="fab fa-youtube"></i></a>
                    </div>
                </div>
                <div class="footer-section">
                    <h3>Quick Links</h3>
                    <ul>
                        <li><a href="../index.html#stories">Stories</a></li>
                        <li><a href="../index.html#tips">Tips</a></li>
                        <li><a href="../index.html#research">Research</a></li>
                        <li><a href="../index.html#resources">Resources</a></li>
                    </ul>
                </div>
                <div class="footer-section">
                    <h3>Alzheimer's Help</h3>
                    <p><i class="fas fa-phone"></i> 24/7 Helpline: <a href="tel:8002723900">800.272.3900</a></p>
                    <p><i class="fas fa-info-circle"></i> Available in 200+ languages</p>
                </div>
            </div>
            <p class="copyright">Â© 2023 Memory Support. All rights reserved.</p>
        </div>
    </footer>
    <script src="../js/main.js"></script>
</body>
</html>
